$1.01
0.50% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US82024L1035
Symbol
STTK
Sector
Industry

Shattuck Labs Inc Stock price

$1.01
-0.30 22.90% 1M
-6.48 86.52% 6M
-6.12 85.83% YTD
-1.29 56.09% 1Y
-9.00 89.91% 3Y
-15.99 94.06% 5Y
-15.99 94.06% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 0.50%
ISIN
US82024L1035
Symbol
STTK
Sector
Industry

Key metrics

Market capitalization $48.22m
Enterprise Value $-38.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.61
EV/Sales (TTM) EV/Sales -5.93
P/S ratio (TTM) P/S ratio 7.49
P/B ratio (TTM) P/B ratio 0.50
Revenue growth (TTM) Revenue growth 382.75%
Revenue (TTM) Revenue $6.44m
EBIT (operating result TTM) EBIT $-79.88m
Free Cash Flow (TTM) Free Cash Flow $-62.64m
Cash position $90.06m
EPS (TTM) EPS $-1.53
P/E forward negative
P/S forward 8.60
EV/Sales forward negative
Short interest 6.90%
Show more

Is Shattuck Labs Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Shattuck Labs Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Shattuck Labs Inc forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Shattuck Labs Inc forecast:

Buy
40%
Hold
60%

Financial data from Shattuck Labs Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6.44 6.44
384% 384%
100%
- Direct Costs 3.87 3.87
10% 10%
60%
2.57 2.57
186% 186%
40%
- Selling and Administrative Expenses 12 12
5% 5%
179%
- Research and Development Expense 67 67
17% 17%
1,041%
-76 -76
20% 20%
-1,180%
- Depreciation and Amortization 3.87 3.87
10% 10%
60%
EBIT (Operating Income) EBIT -80 -80
20% 20%
-1,240%
Net Profit -74 -74
22% 22%
-1,156%

In millions USD.

Don't miss a Thing! We will send you all news about Shattuck Labs Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Shattuck Labs Inc Stock News

Negative
Market Watch
about 2 months ago
The stock hit a low of $1.37 earlier in the session, matching its record closing low that was set in October 2023.
Neutral
GlobeNewsWire
about 2 months ago
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –
Neutral
GlobeNewsWire
4 months ago
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in a fireside chat and one-on-o...
More Shattuck Labs Inc News

Company Profile

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Head office United States
CEO Taylor Schreiber
Employees 75
Founded 2016
Website www.shattucklabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today